NCT04649021View on ClinicalTrials.gov

Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population

PHASE2CompletedINTERVENTIONAL
Enrollment

950

Participants

Timeline

Start Date

December 4, 2020

Primary Completion Date

February 7, 2021

Study Completion Date

January 9, 2022

Conditions
SARS-CoV-2
Interventions
BIOLOGICAL

BNT162b2

Intramuscular injection

OTHER

Placebo

Intramuscular injection

Trial Locations (1)

210009

Jiangsu Provincial Center for Disease Control and Prevention, Jiangsu

Sponsors

Lead Sponsor

BioNTech SE
All Listed Sponsors
collaborator

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

INDUSTRY

lead

BioNTech SE

INDUSTRY

NCT04649021 - Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population | Biotech Hunter | Biotech Hunter